Cellid Co. Ltd
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) an… Read more
Cellid Co. Ltd (299660) - Total Liabilities
Latest total liabilities as of September 2025: ₩33.79 Billion KRW
Based on the latest financial reports, Cellid Co. Ltd (299660) has total liabilities worth ₩33.79 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cellid Co. Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how Cellid Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cellid Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Cellid Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Saraswanti Anugerah Makmur Pt
JK:SAMF
|
Indonesia | Rp1.66 Trillion |
|
IBKS No. 15 Special Purpose Acquisition Co. Ltd.
KQ:373200
|
Korea | ₩46.29 Billion |
|
Berentzen Gruppe AG
XETRA:BEZ
|
Germany | €79.73 Million |
|
Farmsco
KO:036580
|
Korea | ₩901.42 Billion |
|
Coincheck Group N.V. Ordinary Shares
PINK:CNCK
|
USA | $126.65 Billion |
|
Zoomd Technologies Ltd
PINK:ZMDTF
|
USA | $9.45 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Cellid Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cellid Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cellid Co. Ltd (2015–2024)
The table below shows the annual total liabilities of Cellid Co. Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩24.88 Billion | +6.22% |
| 2023-12-31 | ₩23.43 Billion | +0.04% |
| 2022-12-31 | ₩23.42 Billion | +20.12% |
| 2021-12-31 | ₩19.50 Billion | +826.53% |
| 2020-12-31 | ₩2.10 Billion | +77.41% |
| 2019-12-31 | ₩1.19 Billion | +64.58% |
| 2018-12-31 | ₩720.63 Million | -93.13% |
| 2017-12-31 | ₩10.49 Billion | +161.36% |
| 2016-12-31 | ₩4.01 Billion | +114.39% |
| 2015-12-31 | ₩1.87 Billion | -- |